Study of the association between dopamine beta-hydroxylase gene RS1611115 (C-1021T) polymorphism and schizophrenia symptoms in antipsychotic therapy

It is known that disturbances in the functioning of the dopaminergic and noradrenergic systems of the brain are involved in the mechanisms of the development of schizophrenia. An important enzyme involved in the metabolism of dopamine and norepinephrine is dopamine-β-hydroxylase. The established change in the activity of this enzyme in patients with schizophrenia may be due to genetic characteristics. Objective: to study the association of the rs1611115 (C-1021T) dopamine-β-hydroxylase gene polymorphism with the severity of schizophrenia symptoms in patients with the first episode of schizophrenia during therapy with haloperidol and risperidone. Material and Methods. In total, the study included 212 patients of the main group, including 110 men and 112 women. All patients in accordance with ICD-10 were diagnosed with paranoid schizophrenia, follow-up period lasted less than one year, F20.09. The study sample was divided into two clinical groups: group 1 (n=105) - patients took haloperidol, group 2 (n=107) - patients were prescribed risperidone. The control group consisted of 152 people. Human genomic DNA was isolated from whole blood leukocytes. SNP analysis DBH C-1021T rs1611115 was performed by polymerase chain reaction. Results. In patients with schizophrenia, carriers of the reference allele C SNP DBH rs1611115 (C-1021T) were 1.13 times more likely to be present, in whom the risk of developing the disease was 1.8 times increased. It was found that in carriers of the C/T+T/T SNP rs1611115 (C-1021T) genotypes, positive symptoms of schizophrenia were more pronounced than in carriers of the C/C genotype. In carriers of these genotypes, with haloperidol and risperidone therapy, positive and general symptoms were reduced in a shorter time, and with haloperidol -negative ones. Conclusion. Our data demonstrate the possible role of dopamine-β-hydroxylase genetic defects in the mechanisms of schizophrenia development. At the same time, the severity of clinical symptoms in patients with the first episode of schizophrenia before the start of treatment and their dynamics during antipsychotic therapy are also associated with the dopamine в-hydroxylase SNP rs1611115 (C-1021T)